Sök alla kliniska studier, hela Sverige som handlar om Cancer
Databas
Allogena dendritiska celler som antigen-bärare och adjuvans vid terapeutisk vaccination mot cancer.
2009-01-16Alex Karlsson-Parra
Avdelningen för klinisk immunologi och transfusionsmedicin
Not uppdated, final reminder
Vad karakteriserar de män som inbjuds till PSA screening men som dör av prostata cancer?
2008-01-03Anna Grenabo Bergdahl
Avdelningen för urologi, Sahlgrenska universitetssjukhuset
Completed
Utvärdering av munvårdsprogram för patienter som genomgår behandling för cancer i huvud- och halsregionen avseende mukosit, oral hälsa, livskvalitiet och hälsoekonomi
2017-05-31Annica Almståhl
Göteborgs universitet, avd för oral mikrobiologi och immunologi
Published
Skyddseffekt av vaccination hos cancerpatienter under pågående
onkologisk behandling
2018-08-30Antonis Valachis
Onkologiska Kliniken Universitetssjukhuset Örebro
Published
Somatostatin analogen octreotride som tilläggsbehandling för att optimera kroppsvikt och näringsstatus efter botande cancerkirurgi i övre magtarmkanalen
2015-01-12Carel le Roux
Gastroenterologi lab
Not updated
Nya behandlingsmetoder vid komplikationer efter huvud-hals cancerbehandling ger förbättrad funktion och hälsorelaterad livskvalitet - klinisk och translationell forskning
2010-12-15Caterina Finizia
ÖNH-kliniken
Published
Cellsignalering vid cancer:
Identifiering av nyckelmediatorer för förebyggande och behandling av cancer
2009-01-29Dick Delbro
Inst. f. läkarutbildning, Örebro universitet 702 81 Örebro
Not uppdated, final reminder
VINGEM/NUCOG1. En multicenter, randomiserad fas II-studie av Vinflunin / Gemcitabin verus karboplatin / Gemcitabin som första linjens behandling av patienter med metastaserande uroteliala cancer olämpliga för cisplatin på grund av nedsatt njurfunktion.
2015-06-04Elisabeth Öfverholm
*
Not uppdated, final reminder
Rätt dosering av 5-fluorouracil till rätt patient med kolorektal cancer.
2013-04-25Göran Carlsson
Verksamhetsområde Kirurgi, SU/Östra
Not updated
Farmakokinetisk och farmakodynamisk kartläggning av leukovorin i tumör och närliggande tarmslemhinna hos patienter med kolorektal cancer.
2012-06-19Helena Taflin
-
Ongoing revision
Livskvalitet, socialt stigma och cancerrehabiliteringsbehov hos kvinnor med cancer, en enkätstudie i Region Örebro län
2018-03-29Jeanette Kittang
Medicinska behandlingsenheten, Onkologiska kliniken
Published
PREDIX HER2- Neoadjuvant response- guided treatment of HER2- positive breast cancer. Part of set platform of translational phase II trials based on molecular subtypes
2017-06-15Jenny 4 Larsson
Onkologiska kliniken
Published
En fas 2 studie av per oral behandling med digitoxin vid hormonrefraktär prostata-
cancer.
2007-04-04Johan Haux
SkaS Skövde Onk.mott. Kir. kliniken
Not updated
Ultraljud vid cancer i tunga och munbotten
2018-08-30Johan Knutsson
ÖNH-klin Universitetssjh Örebro och Örebro Universitet, samt ÖNH-klin Västmanland
Published
Immunsuppression vid cancer och kronisk virusinfektion - prekliniska och kliniska studier
2008-04-28Kristoffer Hellstrand
Sahlgrenska Cancer Center
Not uppdated, final reminder
Vävnadsreparativa mekanismer, dess betydelse vid sammanväxningar, inflammatoriska tillstånd och cancer. Utveckling av kirurgisk teknik.
2008-03-11Marie-Lois Ivarsson
-
Not uppdated, final reminder
Evidensbaserad palliativ behandling av cancerpatienter med sjuklig viktnedgång; särskilt avseende nutritionella effekter på livskvalitet och funktion.
2007-06-29Marita Fouladiun
Avd för kirurgi
Not uppdated, final reminder
Tryckkammarbehandling vid besvär från urinblåsan som uppkommit efter strålbehandling mot cancer i bäckenregionen.
2010-03-01Nicklas Oscarsson
Angereds Närsjukhus, Opererande Specialiteter
Completed
En ny behandlingsstrategi för ökad bot vid cancersjukdom: Riktad alfa-partikel strålning laddad på tumörsökande antikroppar
2014-12-19Per Albertsson
-
Not updated
Smärta och postoperativ morbiditet efter kirurgi för kolorektal cancer. En jämförelse mellan epiduralanalgesi och patientkontrollerad intravenös analgesi.
2018-08-08Wiebke Siekmann
ANIVA-kliniken, Region Örebro län
Published
A phase I-II study on the treatment with Taxotere in combination with Gemzar in patients with oesophageal cancer or cancer in the cardia region
&
A phase I-II study on the treatment with Taxotere in combination with cisplatin, 5-fluorouracil and radiotherapy in patients with locally advanced but not metastatic oesophageal cancer or cancer in the cardia region
2018-03-27Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
Achiles: A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer
2018-10-02Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Arimidex ± Herceptin: A randomized, controlled, open label study to evaluate the efficacy and safety of trastuzumab in combination with the oral atomatase inhibitor anastrozole compared with anastrozole alone as first and second line treatment administered to postmenopausal, hormone receptor positive patients with HER2 overexpressing metastatic breast cancer
2018-04-09Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
Artscan II: Accelerated radiotherapy of squamous cell carcinoma of head and neck. Preoperative accelerated vs. postoperative conventional radiotherapy in patients with resectable cancer of oral cavity.
2017-09-11Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Artscan III: A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer
2017-08-31Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
BEMP-Assessment of acute side effects effect of 14-14,5 Gy HDR brachytherapy in combination with hypofractionated external beam radiotherapy
(3 Gy x 14) in the treatment of localised prostate cancer with a small external beam margin of 3 mm and real time positioning – a randomized syudy comparing two different overall treatment times
2018-02-19Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
CAOS - An open, randomized, multicenter study in patients with recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer to compare the efficacy and safety of paclitaxel (micellar) nanoparticles and paclitaxel
2018-03-27Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
CompLEEment-1: An open-label, multicenter, phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
2017-06-08Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
CRITICS (ChemoRadiotherapy after Induction chemo Therapy In Cancer of the Stomach):
A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer
2017-09-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
DOCeCAP - Feasibility study with fixed dose of docetaxel in combination with dose escalated capecitabine in metastatic breast cancer
2018-04-03Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
Embrace II: Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer
2018-10-02Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
EXCellent - An open label phase II study of EXC (epirubicin, capecitabine and cisplatin) as primary treatment of locally advanced/inflammatory breast cancer, in an out patient setting
2018-04-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
FACT - Anastrozole monotherapy versus maximaloestrogen blockade with anastrozole and fulvestrant combination therapy: An open, randomized, comperative, phase III multicenter study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumor
2018-03-27Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
First BEAT - First-line bevacizumab and chemotherapy in metastatic cancer of the colon or rectum. An expanded access program.
2018-04-03Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
GA-TAC: A randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid in patients with advanced gastric cancer
2018-04-03Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
HYPO-RT-PC: Phase III study of HYPO-fractionated radiotherapy (HYPO-RT) of intermediate risk localised prostate cancer
2017-09-11Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
ICON7 - A randomized, two-arm, multi-center gynaecologic cancer intergroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
KAITLIN: A Randomised, Multicenter, Open-label, Phase III Trial,
Comparing Trastuzumab plus Pertuzumab plus a Taxane following Antracyclines versus Trastuzumab-Emtansine plus Pertuzumab following Antracyclines As Adjuvant Therapy in Patients with operable HER2-positive Primary Breast Cancer.
2017-09-05Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
LARCT- US - Locally Advanced Rectal Cancer Trial – Uppsala Style
(Single) centre phase II study of short course radiation therapy followed by pre-operative chemotherapy and surgery in primary high-risk rectal cancer
2017-11-22Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Monarch-3: A randomized Double-Blind Placebo-Controlled Phase 3 Study of Nonsteroidal AromataseInhibitors (Anastrozole or Letrozole) plus LY2835219 (a CDK4/6 Inhibitor) or Placebo in Postmenopausal Women
with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting
2017-09-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
NORDIC-9: Full dose monotherapy S-1 (followed by irinotecan) compared
to reduced dose combination therapy (S-1/oxaliplatin followed
by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer.
2017-07-12Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Octavia - A single arm phase II Clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
PALLAS: PALbociclib CoLlaborative Adjuvant Study:
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
2017-07-12Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Planet - Phase II randomized study on Locally Advanced Non small cell lung cancer Escalated dose on individual basia Treatment with radiochemotherapy
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
PUMA-NER: A study of neratinib plus capecitabin versus lapatinib plus capecitabine
on patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting
2017-09-04Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
RAPIDO: Randomized multicenter phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in patients with high risk primary rectal cancer compared to standard preoperative chemoradiotheraphy and surgery and optional adjuvant chemotherapy.
2017-09-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Ribbon: A multicenter, phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer
2018-03-26Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
ROSiA: Global study to assess the addition of bevacizumab to carboplatin and paclitaxel as front-line treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
2018-03-26Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
SBG 2000-1: Individually dose-adjusted FEC compared to standard FEC as adjuvant chemotherapy for node positive or high-risk node negative breast cancer
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
SBG 2004-1 fas 3 (Panther): A randomized phase III study comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel versus three weekly epirubicin + cyclophosphamide, 5-fluorouracil followed by docetaxel in lymph node positive or high risk lymph node negative breast cancer patients – a continuation of the feasibility part of the SBG 2004-1 study
2017-09-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Solar-1: A phase III, randomized, double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
2017-09-05Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
SOLD (The Synergism Or Long Duration Study): A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer
2017-09-06Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
TH3RESA - A phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of trastuzumab emtansine compared with treatment of physicians choice in patients with HER2-positive metastatic breast cancer who have receive at least two prior regimens of HER2-directed therapy
2018-03-21Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
The BOLD-1 Study (Binary HER2 inhibition Or Long Duration-1)
A randomized phase III study comparing trastuzumab,
pertuzumab plus docetaxel (TPD) followed by 3 cycles of
chemotherapy to the current standard regimen as the treatments
of early HER2-positive breast cancer
2017-11-22Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
The SBG 2004-1 study. A phase II study continuing into a randomised phase III study. Comparison of safety, feasibility and efficacy of: dose dense and tailored and dose escalated epirubicin + cyclophosphamide followed by docetaxel or dose dense epirubicin + cyclophosphamide followed by docetaxel or docetaxel + doxorubicin + cyclophosphamide in lymph node positive breast cancer patients.
2018-03-15Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Completed
THORA: A Randomized Phase II Study Comparing Two
Schedules of Hyperfractionated Thoracic Radiotherapy
in Limited Disease Small-Cell Lung Cancer
2017-09-04Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
Viable: A Randomized, Double Blind, Multicenter, Parallel-Group,
Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa
Versus Placebo in Men with Metastatic Castration Resistant
Prostate Cancer Eligible for 1st Line Chemotherapy
2017-09-04Ylva Storck
USÖ, Onkologiska kliniken, Kliniska Prövningsenheten
Published
PublishedDocument information: Sök alla kliniska studier, hela Sverige som handlar om Cancer | Last modified: 2017-09-22 by Researchweb Support

Sök alla kliniska studier, hela Sverige som handlar om Cancer , from FoU i Sverige
http://www.researchweb.org/is/en/sverige/sok/kliniskstudie?extra1=som%20handlar%20om&name=hela%20Sverige&wp=11&field=Cancer